> top > docs > PubMed:23824362 > annotations

PubMed:23824362 JSONTXT

Annnotations TAB JSON ListView MergeView

DisGeNET

Id Subject Object Predicate Lexical cue
T0 1369-1374 gene:672 denotes BRCA1
T1 1393-1400 disease:C1261473 denotes sarcoma
T2 1369-1374 gene:672 denotes BRCA1
T3 1422-1445 disease:C1168401 denotes head and neck carcinoma
R1 T0 T1 associated_with BRCA1,sarcoma
R2 T2 T3 associated_with BRCA1,head and neck carcinoma

Allie

Id Subject Object Predicate Lexical cue
SS1_23824362_1_0 122-150 expanded denotes radiation-associated sarcoma
SS2_23824362_1_0 152-155 abbr denotes RAS
AE1_23824362_1_0 SS1_23824362_1_0 SS2_23824362_1_0 abbreviatedTo radiation-associated sarcoma,RAS

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 143-150 HP_0100242 denotes sarcoma
T2 203-209 HP_0002664 denotes cancer
T3 233-255 HP_0003254 denotes involved in DNA repair
T4 327-339 HP_0200058 denotes angiosarcoma
T5 345-358 HP_0003002 denotes breast cancer
T6 345-358 HP_0100013 denotes breast cancer
T7 352-358 HP_0002664 denotes cancer
T8 510-516 HP_0002664 denotes cancer
T9 542-555 HP_0003002 denotes breast cancer
T10 542-555 HP_0100013 denotes breast cancer
T11 549-555 HP_0002664 denotes cancer
T12 667-674 HP_0100242 denotes sarcoma
T13 1393-1400 HP_0100242 denotes sarcoma

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
23824362-0#80#83#gene7157 80-83 gene7157 denotes p53
23824362-0#44#51#diseaseC1261473 44-51 diseaseC1261473 denotes sarcoma
23824362-11#2#7#gene672 1369-1374 gene672 denotes BRCA1
23824362-11#26#33#diseaseC1261473 1393-1400 diseaseC1261473 denotes sarcoma
23824362-11#55#78#diseaseC3887461 1422-1445 diseaseC3887461 denotes head and neck carcinoma
23824362-3#68#73#gene672 386-391 gene672 denotes BRCA1
23824362-3#78#83#gene675 396-401 gene675 denotes BRCA2
23824362-3#27#40#diseaseC0006142 345-358 diseaseC0006142 denotes breast cancer
23824362-3#27#40#diseaseC0678222 345-358 diseaseC0678222 denotes breast cancer
23824362-3#27#40#diseaseC0006142 345-358 diseaseC0006142 denotes breast cancer
23824362-3#27#40#diseaseC0678222 345-358 diseaseC0678222 denotes breast cancer
80#83#gene715744#51#diseaseC1261473 23824362-0#80#83#gene7157 23824362-0#44#51#diseaseC1261473 associated_with p53,sarcoma
2#7#gene67226#33#diseaseC1261473 23824362-11#2#7#gene672 23824362-11#26#33#diseaseC1261473 associated_with BRCA1,sarcoma
2#7#gene67255#78#diseaseC3887461 23824362-11#2#7#gene672 23824362-11#55#78#diseaseC3887461 associated_with BRCA1,head and neck carcinoma
68#73#gene67227#40#diseaseC0006142 23824362-3#68#73#gene672 23824362-3#27#40#diseaseC0006142 associated_with BRCA1,breast cancer
68#73#gene67227#40#diseaseC0678222 23824362-3#68#73#gene672 23824362-3#27#40#diseaseC0678222 associated_with BRCA1,breast cancer
68#73#gene67227#40#diseaseC0006142 23824362-3#68#73#gene672 23824362-3#27#40#diseaseC0006142 associated_with BRCA1,breast cancer
68#73#gene67227#40#diseaseC0678222 23824362-3#68#73#gene672 23824362-3#27#40#diseaseC0678222 associated_with BRCA1,breast cancer
78#83#gene67527#40#diseaseC0006142 23824362-3#78#83#gene675 23824362-3#27#40#diseaseC0006142 associated_with BRCA2,breast cancer
78#83#gene67527#40#diseaseC0678222 23824362-3#78#83#gene675 23824362-3#27#40#diseaseC0678222 associated_with BRCA2,breast cancer
78#83#gene67527#40#diseaseC0006142 23824362-3#78#83#gene675 23824362-3#27#40#diseaseC0006142 associated_with BRCA2,breast cancer
78#83#gene67527#40#diseaseC0678222 23824362-3#78#83#gene675 23824362-3#27#40#diseaseC0678222 associated_with BRCA2,breast cancer

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 345-351 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
PD-UBERON-AE-B_T2 542-548 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
PD-UBERON-AE-B_T3 1245-1251 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
PD-UBERON-AE-B_T4 716-721 http://purl.obolibrary.org/obo/UBERON_0001443 denotes chest
PD-UBERON-AE-B_T5 716-726 http://purl.obolibrary.org/obo/UBERON_0016435 denotes chest wall
PD-UBERON-AE-B_T6 1422-1426 http://purl.obolibrary.org/obo/UBERON_0000033 denotes head
PD-UBERON-AE-B_T7 1431-1435 http://purl.obolibrary.org/obo/UBERON_0000974 denotes neck

PubCasesHPO

Id Subject Object Predicate Lexical cue
TI1 44-51 HP:0100242 denotes sarcoma
AB1 143-150 HP:0100242 denotes sarcoma
AB2 327-339 HP:0200058 denotes angiosarcoma
AB3 667-674 HP:0100242 denotes sarcoma
AB4 1393-1400 HP:0100242 denotes sarcoma
AB5 1436-1445 HP:0030731 denotes carcinoma

PubCasesORDO

Id Subject Object Predicate Lexical cue
AB1 327-339 ORDO:263413 denotes angiosarcoma

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-94 Sentence denotes Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.
TextSentencer_T2 95-197 Sentence denotes The estimated incidence of radiation-associated sarcoma (RAS) is 0.03-0.2 % in 5 years post treatment.
TextSentencer_T3 198-317 Sentence denotes Most cancer predisposing genes are involved in DNA repair; therefore, elevated RAS risk in these patients is plausible.
TextSentencer_T4 318-411 Sentence denotes Cases of angiosarcoma post breast cancer treatment were reported in BRCA1 and BRCA2 carriers.
TextSentencer_T5 412-532 Sentence denotes We report the genetic evaluation of seven cases with suspected RAS from patients counseled in our cancer-genetic clinic.
TextSentencer_T6 533-642 Sentence denotes Of 2,885 breast cancer patient, 470 were BRCA1 or two mutation carriers and three were p53 mutation carriers.
TextSentencer_T7 643-750 Sentence denotes Of them seven developed sarcoma in the field of irradiation; five in the chest wall and two in other sites.
TextSentencer_T8 751-869 Sentence denotes Genetic evaluation revealed BRCA1 mutation in two, BRCA2 mutation in additional patient and a carrier of p53 mutation.
TextSentencer_T9 870-1043 Sentence denotes The estimation of risk for RAS in patients with genetic predisposition is limited due to the rarity of this event, and the bias in referral to the clinic toward younger age.
TextSentencer_T10 1044-1211 Sentence denotes With these limitations the rate of RAS is 0.43 % (2/470, 95 % CI -0.17 to 1.02, SE = 0.3) in this group in a median follow-up of 8.2 years (range 1 month to 51 years).
TextSentencer_T11 1212-1366 Sentence denotes If we assume irradiation for the breast in 80 % of the patients than rate of RAS in group is proximately 0.53 % (2/376, 95 % CI -0.21 to 1.26, SE = 0.37).
TextSentencer_T12 1367-1481 Sentence denotes A BRCA1 carrier which had sarcoma after irradiation to head and neck carcinoma was not included in these analyses.
TextSentencer_T13 1482-1581 Sentence denotes In conclusion, we found a high frequency of BRCA1/2 mutation among our patients diagnosed with RAS.
TextSentencer_T14 1582-1742 Sentence denotes However, we estimated approximately twofold increase in the risk of RAS in BRCA1/2 carriers which was not significant compared to reports in general population.
TextSentencer_T15 1743-1917 Sentence denotes Therefore, RAS is a rare event in BRCA carriers as in the general population, and should not be considered in the decision regarding irradiation treatment in this population.
T1 0-94 Sentence denotes Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations.
T2 95-197 Sentence denotes The estimated incidence of radiation-associated sarcoma (RAS) is 0.03-0.2 % in 5 years post treatment.
T3 198-317 Sentence denotes Most cancer predisposing genes are involved in DNA repair; therefore, elevated RAS risk in these patients is plausible.
T4 318-411 Sentence denotes Cases of angiosarcoma post breast cancer treatment were reported in BRCA1 and BRCA2 carriers.
T5 412-532 Sentence denotes We report the genetic evaluation of seven cases with suspected RAS from patients counseled in our cancer-genetic clinic.
T6 533-642 Sentence denotes Of 2,885 breast cancer patient, 470 were BRCA1 or two mutation carriers and three were p53 mutation carriers.
T7 643-750 Sentence denotes Of them seven developed sarcoma in the field of irradiation; five in the chest wall and two in other sites.
T8 751-869 Sentence denotes Genetic evaluation revealed BRCA1 mutation in two, BRCA2 mutation in additional patient and a carrier of p53 mutation.
T9 870-1043 Sentence denotes The estimation of risk for RAS in patients with genetic predisposition is limited due to the rarity of this event, and the bias in referral to the clinic toward younger age.
T10 1044-1211 Sentence denotes With these limitations the rate of RAS is 0.43 % (2/470, 95 % CI -0.17 to 1.02, SE = 0.3) in this group in a median follow-up of 8.2 years (range 1 month to 51 years).
T11 1212-1366 Sentence denotes If we assume irradiation for the breast in 80 % of the patients than rate of RAS in group is proximately 0.53 % (2/376, 95 % CI -0.21 to 1.26, SE = 0.37).
T12 1367-1481 Sentence denotes A BRCA1 carrier which had sarcoma after irradiation to head and neck carcinoma was not included in these analyses.
T13 1482-1581 Sentence denotes In conclusion, we found a high frequency of BRCA1/2 mutation among our patients diagnosed with RAS.
T14 1582-1742 Sentence denotes However, we estimated approximately twofold increase in the risk of RAS in BRCA1/2 carriers which was not significant compared to reports in general population.
T15 1743-1917 Sentence denotes Therefore, RAS is a rare event in BRCA carriers as in the general population, and should not be considered in the decision regarding irradiation treatment in this population.

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 1431-1435 http://purl.obolibrary.org/obo/UBERON_0000974 denotes neck
PD-UBERON-AE-B_T2 716-721 http://purl.obolibrary.org/obo/UBERON_0001443 denotes chest
PD-UBERON-AE-B_T3 345-351 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
PD-UBERON-AE-B_T4 542-548 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
PD-UBERON-AE-B_T5 1245-1251 http://purl.obolibrary.org/obo/UBERON_0000310 denotes breast
PD-UBERON-AE-B_T6 716-726 http://purl.obolibrary.org/obo/UBERON_0016435 denotes chest wall
PD-UBERON-AE-B_T7 1422-1426 http://purl.obolibrary.org/obo/UBERON_0000033 denotes head